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Hereditary sensory and autonomic neuropathy type II (HSANII) is a rare autosomal-recessive disorder characterized by peripheral nerve
degeneration resulting in a severe distal sensory loss. Although mutations in FAM134B and the HSN2 exon of WNK1 were associated
with HSANII, the etiology of a substantial number of cases remains unexplained. In addition, the functions of WNK1/HSN2 and
FAM134B and their role in the peripheral nervous system remain poorly understood. Using a yeast two-hybrid screen, we found that
KIF1A, an axonal transporter of synaptic vesicles, interacts with the domain encoded by the HSN2 exon. In parallel to this screen, we
performed genome-wide homozygosity mapping in a consanguineous Afghan family affected by HSANII and identified a unique region
of homozygosity located on chromosome 2q37.3 and spanning the KIF1A gene locus. Sequencing of KIF1A in this family revealed a trun-
cating mutation segregating with the disease phenotype. Subsequent sequencing of KIF1A in a series of 112 unrelated patients with
features belonging to the clinical spectrum of ulcero-mutilating sensory neuropathies revealed truncating mutations in three
additional families, thus indicating that mutations in KIF1A are a rare cause of HSANII. Similarly to WNK1 mutations, pathogenic
mutations in KIF1A were almost exclusively restricted to an alternatively spliced exon. This study provides additional insights into
the molecular pathogenesis of HSANII and highlights the potential biological relevance of alternative splicing in the peripheral sensory
nervous system.Introduction
Hereditary sensory and autonomic neuropathies (HSANs)
are a clinically and genetically heterogeneous group of
neurological conditions characterized by peripheral nerve
degeneration resulting in a loss of sensory perception
accompanied by variable degrees of autonomic dysfunc-
tion.1,2 Mutations in several genes were identified for auto-
somal-recessive (WNK1 [MIM 605232], NTRK1 [MIM
191315], IKBKAP [MIM 603722], NGFB [MIM 162030],
CCT5 [MIM 610150], and FAM134B [MIM 613114])3–9
and autosomal-dominant (SPTLC1 [MIM 605712], SPTLC2
[MIM 605713], RAB7 [MIM 602298], and ATL1 [MIM
606439]) forms 10–13 of HSANs. Hereditary sensory and
autonomic neuropathy type II (HSANII [MIM 201300]) is
characterized by a recessive inheritance, onset of symptoms
in the first decade of life, and severe distal sensory loss with
minimal autonomic dysfunction.14,15We previously estab-
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The Americexon of WNK1 cause HSANII3,4 and reported that two
founder mutations in the HSN2 exon were responsible for
the higher prevalence of HSANII in the French-Canadian
population of Quebec.16 Although mutations in WNK1
and FAM134B were shown to cause HSANII in some fami-
lies,3,4,9 the etiology of a substantial number of cases
remains unexplained.17 In addition, the functions of
WNK1/HSN2 and FAM134B and their role in the peripheral
nervous system remain poorly understood.
To understand the disease pathophysiology and WNK1/
HSN2 function, we used a yeast two-hybrid (Y2H) screen to
identify proteins interacting with the domain encoded by
the HSN2 exon. We also performed genome-wide homozy-
gosity mapping in a consanguineous Afghan family
affected by HSANII. These two parallel approaches
converged to the identification of causative mutations for
HSANII in KIF1A (MIM 601255), which is a gene encoding
a motor protein involved in the anterograde transport of
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Material and Methods
Yeast Two-Hybrid Screen
A human cDNA encoding the HSN2 exon was subcloned in
a pGBKT7 bait vector (Clontech, #630443) so that it could be
expressed as a bait GAL4DNA binding domain (BD) fusion protein
when transformed in S. cerevisiae AH109 (MATa) (Clontech,
#630444). We performed a Y2H screen by mating these cells
with Y187 cells (MATa) pretransformed with an oligo(dT) human
fetal brain cDNA library (Clontech, #638869). The prey proteins
encoded in Y187 cells are GAL4 activation domain (AD) fusion
proteins. As a positive control, AH109 pretransformed with
pGBKT7-53 were mated with Y187 pretransformed with
pGADT7-T (MatchMaker positive vectors, Clontech). These
diploid cells are transcriptionally active for their reporter genes,
and colonies grow on SD/-LW. As a negative control, these diploid
cells were tested on SD/-LWHAmedium. The stringency of diploid
clones was controlled with a 3-amino-1,2,4-triazole concentration
(1 mM 3-AT) on minimal medium lacking Leu, Trp, and His, and
the clones were tested for B-galactosidase activity by overlay.
Unique interactors were identified by PCR, digestion profiles
(HaeIII), and sequencing. To define the protein segments of
KIF1A interacting with the domain encoded by the HSN2 exon,
we subcloned 17 fragments of KIF1A in pGADT7, transformed
them in Y187, and mated the cells as described above with
AH109 yeast cells expressing pGBKT7-HSN2.
Coimmunoprecipitation and Immunolotting
Cultured human embryonic kidney cells (HEK293) were trans-
fected with an N-tagged truncated version of WNK1/HSN2
(domains encoded by exons 1 to the HSN2 exon and a Myc tag
in the N terminus) for 48 hr with Lipofectamine Plus. After cell
lysis and centrifugation, the supernatants were precleared and
immunoprecipitated with Dynabeads Protein G (Invitrogen,
#100-03D) complexed to mouse monoclonal anti-KIF1A (8 mg)
(BD Transduction Laboratories, #612094) or species- and isotype-
matched IgG1 (R&D Systems, #MAB002) overnight on a rotator
at 4C. After extensive washes with cold PBS, samples were eluted
from the beads and analyzed, separated by SDS-PAGE, transferred
to nitrocellulose, and immunoblotted. Monoclonal anti-HSN2
(Novus Biologicals, NBP1-32917) and anti-KIF1A (BD Transduc-
tion Laboratories, #612094) antibodies were used for the detection
of WNK1/HSN2 and KIF1A, respectively.
Patients and DNA Samples
Informedwritten consent was obtained from each individual prior
to enrollment in the study. All procedures were approved by the
local ethics committees on human experimentation. The study
included a consanguineous Afghan family affected by HSANII,
112 additional unrelated HSAN cases, and 665 unrelated European
control subjects who were screened for KIF1Amutations. Standard
methods were used for blood sampling and DNA extraction from
peripheral blood.
Genome-wide SNP Genotyping
and Homozygosity Mapping
DNA samples from the three affected siblings and their father were
genotyped with the Illumina HumanHap300-Duov2 Genotyping
BeadChip (HumanHap300v2_A) at the McGill University and
Ge´nome Que´bec Innovation Centre. Genotyping was performed
according to the manufacturer’s instructions. The call rate of the220 The American Journal of Human Genetics 89, 219–230, August 1four samples was greater than 98%. The 318,237 genotyped single
nucleotide polymorphisms (SNPs) were analyzed with the ‘‘runs of
homozygosity’’ tool available in the PLINK software (v1.05)19 so
that homozygous intervals across the 22 autosomes could be
mapped. For identification of homozygous intervals, a fixed
threshold of 1 Mb in length was used. Five missing calls and one
heterozygous SNP within a segment were allowed.
KIF1A Mutation Screening and Haplotype Analysis
All the coding exons of KIF1A (GenBank accession number:
AB290172.1) were amplified by PCR with the primers listed in
Table S1, available online. Primers were designed to amplify
fragments covering coding exons and their intronic flanking
regions. PCR products were sequenced on a 3730XL DNA analyzer
at the McGill University and Ge´nome Que´bec Innovation Centre.
Mutations were confirmed by reamplification of the fragment and
resequencing of the proband and its available relatives. Mutation
Surveyor (version 3.10, SoftGenetics) was used for mutation-
detection analysis. For the purpose of haplotype analysis, 34 single
nucleotide polymorphisms (SNPs) located within the KIF1A locus
were genotyped by PCR amplification and sequencing in the
affected individuals carrying the c.2840 delT mutation and in
their parents.
Analysis of KIF1A Splicing Events by Reverse
Transcriptase PCR
cDNA synthesis and PCR analysis were performed via standard
methods. Total RNA (1 mg) from commercially available RNA
samples (Clontech) was used as template for first-strand cDNA
synthesis. Long-range PCR was performed with Long PCR Mix
(Fermentas). Beta-actin (encoded by ACTB [MIM 102630]) was
coamplified as an internal control to correct for loading variations.
The amplified fragments were analyzed by agarose gel electropho-
resis, and sequence analysis was performed. Oligonucleotide
sequences are listed in Table S1.
Quantitative Real-Time PCR Experiments
Total RNA samples (1 mg) from adult human brain and dorsal root
ganglia (DRG) (Clontech) were used as templates for first-strand
cDNA synthesis. Real-time quantitative PCR experiments were
performed on an ABI 7900HT Real-Time Instrument (Applied
Biosystems) with QuantiTect SYBR green (QIAGEN). The KIF1A
isoform lacking exon 25b was amplified with a forward primer
flanking the splice junction of exons 25 and 26 and a reverse
primer in exon 27. The KIF1A exon-25b-containing isoform was
amplified with primers in exon 25b and 27. PCR primer pairs are
listed in Table S1. POLR2A (MIM 180660) was selected as the
endogenous reference on the basis of its constant expression in
different tissues.20 Relative expression levels of KIF1A isoforms
were calculated with the 2-DDCT method.21 All data are expressed
as means 5 standard error of the mean (SEM) of three indepen-
dent experiments performed in triplicate.
Immunodetections of Primary-Neuron Culture
Adult-mouse sensory neuronal cultures and immunodetections
were performed essentially as described previously.4 Dorsal root
ganglia were dissected from adult mouse C57BL/6 and incubated
with 10 mg/ml of collagenase D (Roche) for 45 min at 37C.
Trypsin (0.25%) was then added for 30 min at 37C. The tissues
were washed once with cold Neurobasal medium (Invitrogen)
plus 2% inactivated goat serum and then triturated in warm2, 2011
Figure 1. Yeast Two-Hybrid Screen for Interactors with the Domain Encoded by the HSN2 Exon
(A) PCR confirmation of the presence of the HSN2 exon in the pGBKT7 vector; the nature of the excised band was confirmed by direct
sequencing.
(B) Y2H assays between domain encoded by the HSN2 exon and some of the identified interactors inserted in pGADT7 vector (KIF1A is
clone #23). To test the interaction, we first grewmated yeasts on a plate with thematingmedium (left panel. SD/-LW, lacking leucine and
tryptophan), then transferred them onto a plate with the selection medium (right panel. SD/-LWHA, lacking leucine, tryptophan,
histidine, and adenine). As a control, empty pGBK constructs were used against the interactors (top lane), and empty-pGAD constructs
were used against the pGBKT7-HSN2 (bottom right corner).
(C) Separate Y2H interaction assays between the domain encoded by the HSN2 exon and 17 overlapping fragments of KIF1A, as shown
in (D). The KIF1A lane corresponds to the full-length cDNA clone.
(D) Schematic representation of the 1791 amino acids of KIF1A (with regions encoded by exons 13b and 25b) showing breakpoints for
the 17 fragments used in (C). Blue numbers indicate which exons were included so that each fragment could be generated. Exon
numbers with a þ sign indicate that the majority of the exon was included in that fragment. Fragments indicated by blue arrows
(1, 2, 3, 8, and 11) showed the strongest affinity for the domain encoded by the HSN2 exon.Neurobasal medium plus serum. One milliliter of the cell suspen-
sion was overlaid on 1 ml of 35% Percoll in saline (Pharmacia;
Amersham Biosciences) and centrifuged at 10C at 285 3 g for
15 min. The cell pellet, which included sensory neurons, was
washed in 5 ml of fresh medium, resuspended in fresh warm
medium with 50 ng/ml of nerve growth factor, and plated on
pol-d-lysine- and laminin-coated coverslips. Depending on
whether or not they were to be infected with lentiviral particles,
cells were cultured for 5 days or 48 hr, respectively, prior to their
immunodetection. A mouse anti-KIF1A (1:200; BD Transduction
Laboratories, #612094), a previously described rabbit anti-
WNK1/HSN2,4 and beta III tubulin (1:2,000; Abcam, #ab41489)
were used for triple immunolabeling of the neurons. Confocal
microscopy analysis was performed with a Leica TCS SP5 broad-
band confocal microscope as previously described.4
Lentiviral shRNA-Mediated Knockdown of KIF1A
Lentiviruses were produced frompLKO.1 vector containing a short
hairpin RNA (shRNA) sequence targeting the KIF1A gene. After
immunoblot detections, two clones (Open Biosystems) that
efficiently silenced the expression of KIF1A were chosen for
neuronal infections (kif43 #TRCN0000091343 and kif46
#TRCN0000091346); control infections were made with another
clone from Open Biosystems (shGFP #RHS4459). For lentiviruses
production, 293FT packaging cells were cotransfected with theThe AmericViraPower Packaging Mix (Invitrogen) and the vector of interest.
The supernatant was collected after 3 days, filtered, and either
used directly on cells or concentrated via ultracentrifugation. Titer
for each virus production was evaluated with serial dilution of the
supernatant and infection of 293 cells. ShGFP at 3 3 106 TU/ml,
kif43 at 3.9 3 106 TU/ml, and kif46 at 3.2 3 106 TU/ml were
used (TU ¼ transducing unit). Pregnant mice were sacrificed at
embryonic day 15.5 (E15.5) so that dissociated primary cortical
neurons could be prepared essentially as described previously.4
The freshly plated primary neurons were kept in a humidified
incubator at 37C for one night before they were infected
overnight with the viral particles described above; growing cells
for 4 days after infection allowed shRNA silencing. Whole-cell
protein lysates were then prepared with SUB lysis buffer and
resolved by SDS-PAGE. The anti-KIF1A antibody was used at
1:1,000, and an anti-actin (Sigma) was used at 1:5,000.Results
KIF1A Interacts with the Domain Encoded
by the HSN2 Exon ofWNK1
To identify proteins interacting with the HSN2 exon of
WNK1, we performed a Y2H screen by using a human
fetal brain cDNA library (bait, pGBKT7-HSN2 [Figure 1A];an Journal of Human Genetics 89, 219–230, August 12, 2011 221
Figure 2. Transient Expression ofWNK1/HSN2 andDetection of
Its Interaction with Endogenous KIF1A
Whole-protein lysates prepared from HEK293 cells transfected (T)
with truncated (180 KDa) WNK1/HSN2 and nontransfected cells
(NT) were immunoprecipitated (IP) with commercial KIF1A
antibody and control IgG1 isotype antibody before they were
loaded and separated by SDS-PAGE. The gel was transferred to
a nitrocellulose membrane and separately immunoblotted (IB)
with anti-HSN2 or anti-KIF1A antibodies. Supernatants of the
immunoprecipitations were also collected. Anti-KIF1A immuno-
precipitation showed the presence of a protein with the appro-
priate size (180 KDa) when anti-HSN2 was used.prey, pGADT7-human fetal brain cDNA library). One of
the positive clones identified corresponded to KIF1A
(Figure 1B). We validated this initial interaction by per-
forming a direct Y2H assay with pGBKT7-HSN2 and
pGADT7-KIF1A (cDNA clone from Kazusa DNA Research
Institute) (Figure 1C, KIF1A lane). We then performed
separate Y2H interaction assays between the domain
encoded by the HSN2 exon and 17 overlapping fragments
of KIF1A and identified three distinct KIF1A segments
interacting with the domain encoded by the HSN2 exon
(Figures 1C and 1D). Coimmunoprecipitation of KIF1A
and WNK1/HSN2 from HEK293 cells expressing a trun-
cated form of WNK1/HSN2 further validated the interac-
tion between WNK1/HSN2 and KIF1A (Figure 2).Clinical Description of the Afghan Family
Three Afghan brothers born from first-degree cousins pre-
sented at Shariati Hospital, Tehran, and were accompa-
nied by their father. The index patient (individual IV:2,
Figure 3) was 13 years of age and reported an age of onset
of 10 years. He presented with numbness in his feet and
hands and mutilation of the fingers and toes but did
not complain of weakness. The problem had gradually
worsened, and he had developed ulcerative lesions refrac-
tory to therapy; these lesions led to amputation. The
patient’s past medical history was unremarkable, and he
had no other neurological disorders. On examination,
his mental state and cranial nerves were normal. Muscle
strength was normal in the proximal upper extremities.
In the hands, the first dorsal interossei was 4/5, the
abductor pollicis brevis was 3/5, and the finger extension
was 4/5. Intrinsic hand muscles were slightly wasted. In
the lower extremities, hip flexors were 5/5, foot dorsiflex-
ors were 0/5, and plantar flexors were 4/5. He had wasting
of the pretibial and calf muscles. Deep tendon reflexes
were generally absent. All fingers were mutilated, and
only one toe was intact. Pinprick and touch were normal,
but vibration and position sense was absent in his feet222 The American Journal of Human Genetics 89, 219–230, August 1and hands. Nerves were not hypertrophic. Nerve-conduc-
tion studies showed normal ulnar motor, reduced median
compound muscle action potential (CMAP) amplitude,
and slightly reduced motor velocities. Tibial and peroneal
motor potentials were absent; sural and superficial pero-
neal sensory potentials were absent; and ulnar and
median sensory potentials had a very low amplitude.
Motor unit action potentials (MUAPs) were neurogenic
in the first dorsal interosseus (FDI) and tibialis anterior
(TA) muscles.
Patient IV:3 was 9 years old. Clinical manifestations had
started a year earlier and included mutilation of the digits,
particularly the toes, which were all mutilated on examina-
tion. Muscle strength was normal in the upper extremities,
where there was no wasting. Hip flexors, quadriceps, and
gastrocnemius were 5/5; foot dorsiflexors were 4/5; and
leg and foot muscles were wasted. Deep tendon reflexes
were 1þ in upper extremities, and knee and ankle jerks
were absent. Pinprick and touch senses were normal, and
vibration was impaired in the feet and hands. Median
and ulnar motor nerve conduction velocities (NCVs)
were normal. Tibial and peroneal CMAPs were absent.
Sural, median, and ulnar sensory potentials were absent.
Needle examination of tibialis anterior muscle showed
neurogenic MUAPs.
Patient IV:4 was 7 years old at examination and pre-
sented with mutilation of the right foot. The left foot
and fingers had only minor changes, and there was no
muscle wasting. Muscle strength was normal except for
foot dorsiflexors, which were 4þ/5. Deep tendon reflexes
in the biceps and the triceps were 1þ; deep tendon reflexes
in the knee, ankle, and brachioradialis were absent.
Pinprick sense was normal; vibration and position
senses were impaired in the hands and feet. There was no
nerve hypertrophy. Median and ulnar motor NCVs were
normal. Tibial and peroneal CMAPs were of low amplitude
and had slightly reduced onduction velocities. Sural
sensory potential was absent; median and ulnar sensory
potentials were of very low amplitude and had mildly
reduced conduction velocities. Needle examination of ti-
bialis anterior muscle showed mildly neurogenic MUAPs.
Overall, the clinical picture was consistent with an
ulcero-mutilating sensory neuropathy with prominent
involvement of position and vibration senses and concom-
itant distal motor involvement, particularly in the feet.
Genome-wide Homozygosity Mapping
Genetic analysis of the Afghan family revealed neither
mutation in WNK1 nor linkage to the WNK1 chromo-
somal locus. Given the parental consanguinity, we per-
formed a homozygosity mapping to map the disease locus.
A unique region of homozygosity larger than 1 Mb was
identified on chromosome 2q37.3-qter spanning 2.68 Mb
and comprising 38 known genes (Table 1), among which
is KIF1A, which encodes the protein we identified in our
Y2H screen. Marker rs1465820 was identified as the
proximal recombinant breakpoint, and no distal2, 2011
Figure 3. Family Tree of the Afghan HSANII Family and Haplotype Analysis of the 2q37.3-qter Chromosomal Region Identified by
Genome-wide Homozygosity Mapping
The parents of the patients are first-degree cousins. Only DNA samples from the father and his three affected sons were available.
Genotyping data from 20 informative SNPs among the 276 SNPs spanning the 2q37.3 locus found in a homozygous state in all three
patients as well as two proximal recombinant markers (patient IV:2, rs6543570 and rs1465820) are shown.recombination event occurred. Among the 276 consecu-
tive SNPs homozygous for the same alleles in the three
affected individuals, 105 were found in a heterozygous
state in the father, as expected for a recessive mode of
inheritance (20 of them are shown in Figure 3).
KIF1A Mutation Screening and Haplotype Analysis
Previously reported homozygous KIF1A-knockout mice
showed severe motor and sensory deficits and a substantial
extent of neuronal death.22 These observations led us to
speculate that the interaction between the domain
encoded by the HSN2 exon of WNK1 and KIF1A was rele-
vant to the pathogenesis of HSANII. KIF1A comprises 47
exons (46 coding) plus three alternatively spliced coding
exons that we here refer to as 13b, 25b, and 36b.
Sequencing of the coding exons and flanking intronic
sequence of the gene in the Afghan family revealed
a 1 bp deletion (GenBank accession number AB290172.1:
c.2840delT [p.Leu947Argfs*4]) in the alternatively spliced
exon 25b, which would be predicted to cause a frameshift.
This mutation was homozygous in all three affected indi-
viduals, heterozygous in the father (family 1, Figure 4),The Americand not present in 665 population controls of European
ancestry. We then screened KIF1A in a cohort of 112 unre-
lated HSAN cases negative for mutations in the HSN2
exon; 23 of these cases were HSANII (Table 2). The
c.2840delT mutation was again found in a homozygous
state in four patients from two unrelated families from
Turkey and Belgium (families 2 and 3, Figure 4) and in
a heterozygous state in another Belgian patient. This last
individual also carried in exon 46 a heterozygous 1 bp
insertion predicted to cause a frameshift and a premature
stop codon (GenBank accession number AB290172.1:
c.5271dupC [p.Ser1758Glnfs*7]). Segregation analysis
confirmed the compound heterozygous state of this last
patient; the c.2840delT and c.5271dupC mutations were
transmitted by the mother and father, respectively
(family 4, Figure 4). No truncating mutations in KIF1A,
either in a heterozygous or in a homozygous state,
were detected in the 665 control individuals (1330
chromosomes), further confirming that truncating
mutations in KIF1A cause HSANII. Haplotype analysis
by genotyping 34 SNPs located within the KIF1A locus
in all four families identified a shared haplotype ofan Journal of Human Genetics 89, 219–230, August 12, 2011 223
Table 1. Shared Homozygous Regions Identified by Genome-wide Homozygosity Mapping in the Afghan Family
Chromosome
Homozygous
SNPs Informative SNPs
Proximal
Recombinant
Breakpoint
Distal
Recombinant
Breakpoint Interval (NCBI36/hg18) Size (Mb)
2 276 105 rs1465820 qter 240,270,700–242,951,149 2,680,449
12 53 0 rs149411 rs590460 48,736,243–49,666,499 930,256
2 50 0 rs707718 rs11898850 72,209,957–73,053,127 843,107
5 70 29 rs6867206 rs4507452 50,688,451–51,468,426 779,975
4 69 3 rs6841266 rs2293131 190,271,285–190,979,685 708,400
18 63 0 rs8087644 rs1561234 49,683,496–50,225,187 541,691
6 64 0 rs1418968 rs1390459 18,881,077–19,411,155 530,078
13 50 0 rs462954 rs1929185 91,169,091–91,696,831 527,740
2 57 22 rs2583526 rs1401838 76,038,324–76,486,648 448,324
5 60 22 rs4074670 rs4701077 178,137,065–178,536,983 399,918
2 57 0 rs4854306 rs6757749 423,274–812,116 388,842
4 51 0 rs1510716 rs13128291 28,138,936–28,499,076 360,140
22 51 0 rs8137243 rs4044210 44,822,499–45,164,979 342,480
10 52 19 rs17157052 rs11251048 1,853,551–2,110,407 256,856
SNP: single-nucleotide polymorphism. Mb: megabase pairs. Informative SNPs: SNPs found in a heterozygous state in the father. Only regions larger than 250 kb
are shown.approximately 45 kb flanking the c.2840delT mutations.
However, given the high frequency of this haplotype block
in the HapMap CEU population, it remains unclear
whether these mutations originated from a commonFigure 4. KIF1A Mutations in Individuals with HSANII
(A) Family trees and segregation analysis of the mutations.
(B) Sequencing traces of the mutations. Abbreviations are as follows
(C) Linear protein structure of KIF1A indicating the kinesin motor d
homology domain (PH). Arrowheads above the protein indicate the
224 The American Journal of Human Genetics 89, 219–230, August 1ancestor or arose independently (Table 3). Affected indi-
viduals from three of the four families (families 1, 2, and
4) with KIF1A mutations were initially diagnosed with
HSANII. Patients from the fourth family (family 3) had: mut, mutated sequencing trace; WT, control sequencing trace.
omain, the Forkhead-associated domain (FHA), and the Pleckstrin
position of the mutations.
2, 2011
Table 2. HSAN Individuals Screened for KIF1A Mutations
Type Inheritance
Unrelated
Individuals
HSANI/HSANIB/CMT2B AD 28
HSANII AR 23
HSANIII AR 2
HSANIV AR 4
HSANV AR 1
HSAN with spastic
paraplegia and/or
pyramidal-tract signs
AR 7
Unspecified unknown 47
Total 112
Inclusion criteria: unrelated patients with clinical features belonging to the clin-
ical spectrum of ulcero-mutilating sensory neuropathies. 62 patients were
negative for mutations in the HSN2 exon of WNK1 and for mutations in
SPTLC1, RAB7,WNK1, NTRK1, NGFB, and CCT5.17 Abbreviations are as follows:
CMT2B, Charcot-Marie-Tooth neuropathy type 2B; AD, autosomal dominant;
AR, autosomal recessive.a slightly later age of onset and, despite the lack of
evidence for an autosomal-dominant pattern of inheri-
tance, were diagnosed as having a severe form of HSANI
(Table 4). Similarly to patients presenting with WNK1
mutations3 and unlike patients with FAM134B muta-
tions,9 individuals with KIF1A mutations showed no clin-
ical autonomic dysfunction.Analysis of KIF1A Splicing Events
Exon 25b was originally identified in a brain-expressed
human mRNA, and this isoform is predicted to encode
a 1791 amino acid peptide (GenBank accession number
BAG06726.1). A sequence cluster alignment based on
multi-species alignment from the UCSC Genome Browser
indicated that this exon and its splice junctions are
conserved through evolution (Figure S1). To further
confirm that exon 25b is an alternatively spliced exon of
KIF1A, we performed RT-PCR reactions with human RNA
samples and primers located within exon 25b and its
neighboring exons (Figures 5A and 5B) and observed that
the KIF1A exon-25b-containing isoform was strongly ex-
pressed in the nervous system. Real-time quantitative
PCR experiments revealed that the KIF1A isoform lacking
exon 25b was the most abundant form in both adult brain
and DRG. The relative abundance of the exon-25b-con-
taining isoform was nonetheless higher in the DRG
(Figure 5C), which is consistent with the peripheral
nervous system phenotype observed in patients lacking
this isoform. Long-range RT-PCR reactions were initiated
with sets of primers flanking the region between the first
coding exon of KIF1A and exon 25b and the region
between exon 25b and the last exon of KIF1A; sequencing
PCR products confirmed the extent of the entire coding
sequence of this specific isoform in the brain and DRG
(Figures 5D and 5E).The AmericImmunodetections of WNK1/HSN2 and KIF1A
and shRNA-mediated Knockdown of KIF1A
in Primary-Neuron Culture
To follow up on our observations that WNK1/HSN2 and
KIF1A interact at the protein level, we used anti-HSN2
and anti-KIF1A antibodies to examine the localization of
the two proteins in cultured primary sensory neurons
prepared from adult mouse DRG. Both proteins were
found to localize in cell bodies and along axons (Figures
6A–6E). Using identical cells, our group previously showed
that WNK1 localized exclusively in the cell body, whereas
WNK1/HSN2 localized in both the cell body and the
axons.4 Given the localization of this second isoform
and the well-established role of KIF1A in anterograde
transport, we hypothesized that KIF1A could be respon-
sible for the anterograde transport of WNK1/HSN2 along
axons.18 To test this hypothesis, we used lentiviral delivery
of shRNAs to silence KIF1A (Figures 6F–6J). Infection of
cultured DRG sensory neurons substantially reduced
KIF1A in cell bodies and rendered it undetectable in axons
(Figure 6G) but did not reduce WNK1/HSN2 in axons
(Figure 6H). This last observation suggests that KIF1A
might not be the only transporter of WNK1/HSN2 along
axons. However, we cannot rule out the possibility that
the reduced remaining amount of KIF1A protein (Figures
5F and 5G) was still sufficient for the transport of
WNK1/HSN2.Discussion
Our study used two parallel approaches, homozygosity
mapping and identification of the binding partners of
the domain encoded by the HSN2 exon. These
approaches converged to allow us to identify HSANII-
causative mutations in the KIF1A gene. Similarly to muta-
tions in the HSN2 exon ofWNK1,4,17 all the patients carry
mutations in an alternatively spliced exon, at least in
a heterozygous state. The HSANII link to the alternatively
spliced exon 25b of KIF1A is further supported by Y2H
data that showed that, in addition to other regions of
KIF1A, the amino acids encoded by this exon participate
in the interaction with theHSN2portionofWNK1 (Figures
1C and1D). Similarly toHSANII patientswithWNK1muta-
tions, all individuals with KIF1Amutations presented with
marked sensory loss and severe mutilations. However, they
also showed distal muscle weakness, which is not a typical
feature of HSANII patients (Table 4). A variable motor
involvement is nonetheless well documented in other
HSAN types, particularly in the autosomal-dominant
forms.10–13
The only compound heterozygous patient with a muta-
tion in exon 46 exhibits the most severe motor phenotype
and is the only one presenting with developmental delay
and short stature (Table 4); an interesting observation
when one considers that homozygous KIF1A-knockout
mice display severe motor and sensory deficits, die withinan Journal of Human Genetics 89, 219–230, August 12, 2011 225
Table 3. Haplotype Sharing in Patients with the c.2840delT Mutation
SNP ID (rs) Position (NCBI36) Alleles Family 1 Family 2 Family 3 Family 4 Shared Allele Frequency
rs755302 241,301,068 G/A G G G G G G A G G G ¼ 50%
rs4613 241,301,960 A/G G G A A A A G A A A ¼ 64%
rs3732341 241,304,217 G/A G G A A A A A A A A ¼ 46.7%
rs3772050 241,321,413 T/C C C C C C C C C C C ¼ 76.7%
rs11886658 241,324,642 G/A G G G G A A A A A A ¼ 50%
rs10174559 241,325,449 G/A G G G G G G G G G G ¼ 78.3%
rs7578279 241,325,937 T/C T T C C T T T T T T ¼ 39.2%
rs3772054 241,327,201 A/G A A A A A A A A A A ¼ 66.7%
rs4414678 241,329,306 G/T T T T T T T T T T T ¼ 35.1%
rs1013225 241,329,317 C/G G G G G G G G G G G ¼ 73.6%
rs56024577 241,329,475 A/G A A A A A A A A A A ¼ 26.9%
rs3755534 241,330,687 A/G A A G G G G G G G G ¼ 85%
rs3772056a 241,332,581 A/G G G G G G G G G G G ¼ 71%
rs7576602a 241,333,365 C/T C C C C C C C C C C ¼ 78.8%
rs10196604 241,334,748 C/T C C C C C C C C C C ¼ 72.6%
rs3755535a 241,336,265 A/C A A A A A A A A A A ¼ 40%
rs11693670 241,340,129 C/G G G G G G G G G G G ¼ 47.5%
rs12624059a 241,341,913 A/G G G G G G G G G G G ¼ 69.2%
rs4676447a 241,343,769 C/T C C C C C C C C C C ¼ 40%
p.Leu947Argfs*4 241,345,427 c.2840 delT delT delT delT delT delT delT T delT delT
rs7598218a 241,346,971 A/G G G G G G G G G G G ¼ 61.7%
rs11688298 241,351,234 A/T T T T T T T T T T T ¼ 45.4%
rs3821345a 241,352,633 G/T G G G G G G G G G G ¼ 39.2%
rs11690282a 241,353,054 C/T T T T T T T T T T T ¼ 77.6%
rs3755536 241,354,706 A/G G G G G G G G G G G ¼ 70.7%
rs11681427 241,354,900 C/T C C C C C C C C C C ¼ 77.5%
rs2288751a 241,362,102 T/C T T T T T T T T T T ¼ 60.8%
rs1063353 241,362,319 C/T T T T T T T T T T T ¼ 64.9%
rs2288750 241,371,118 C/T C C C C C C T C C C ¼ 80.6%
rs2288746 241,375,319 C/T C C T T T T C T T T ¼ 58.5%
rs12989742 241,377,750 C/T T T C C T T C T T T ¼ 69.2%
rs6708456 241,378,666 C/T C C T T C C T C C C ¼ 69.2%
rs6732174 241,380,213 C/T C C T T C C T C C C ¼ 71.7%
rs734586 241,383,427 A/G A A G G A A G A A A ¼ 58.3%
rs7599943 241,390,650 C/T C C T T C C T C C C ¼ 66.7%
Haplotype blocks shared by two or more families are indicated in bold. Alleles shared by all affected individuals are indicated in italics. Allele frequencies were either
derived from the CEU HapMap database or from direct sequencing of the coding exons of KIF1A in our 665 population controls of European ancestry. To estimate
the frequency of the 45 kb haplotype shared by all four families (dark gray shading), we used the phasing data of the HapMap3 project for the CEU population.
Genotyping data were available for nine (indicated by a superscript ‘‘a’’) of the 16 SNPs constituting this haplotype. The ‘‘GCAGCGGTT’’ haplotype identified in
the HSANII families was found at a frequency of 0.37 in the CEU population (87/234 chromosomes). The probability of n independent mutational events for the
c.2840delT mutation on a haplotype whose frequency is 0.37 was calculated as follows: p ¼ 0.37n, giving p ¼ 0.019, p ¼ 0.05, and p ¼ 0.14 for four, three, and
two independent mutational events, respectively.a day of birth, and are significantly smaller than their litter-
mates.22 We could thus speculate that as a result of the
central role of KIF1A in neurons,23 homozygous loss-of-226 The American Journal of Human Genetics 89, 219–230, August 1function mutations in exons that are always spliced-in
may either be lethal or lead to a more severe phenotype
than HSANII. However, further families and pathogenic2, 2011
Table 4. Clinical Features of Affected Individuals with KIF1A Mutations
Family PID AOO AE
Sensory
Symptoms Skin Changes Amputations
Muscle
Weakness
Nerve Conduction
Study
Intellectual
Disability
Additional
Information
Family 1 Afghanistan
HSANII
IV:2 10 13 distal loss of vibration
sense and proprioception
ulcerations yes, digits and toes distal UL and LL see detailed clinical
description in the
Results section
no
IV:3 8 9 ulcerations yes, digits and toes distal LL no
IV:4 6 7 ulcerations yes, toes mild in distal LL no
Family 2 Turkey
HSANII
IV:1 7 22 painless ulcerations ulcerations,
skin grafts
yes distal LL, mild
in distal UL
absent median SNAPs
and muscle denervation
no seizures at age 18; renal
AA amyloidosis
IV:4 9 20 painless ulcerations ulcerations no distal LL, mild
in distal UL
right radial SNAP 3uV,
normal motor conduction.
Muscle denervation
no
Family 3 (CMT-155)
Belgium
HSANI
II:2 15 61 panmodal distal
sensory loss
ulcerations right lower leg
(age 23), all
fingers except
thumbs
(spontaneous
amputations)
complete paralysis
(0/5) distal
left LL, normal
strength in wrists
no spontaneous pains UL
and LL, absent tendon reflexes.
Tibial and fibular nerve biopsy
in amputated limb: thickened
peri- and epineurium with near
complete loss of myelinated axons
II:3 13 61 panmodal distal
sensory loss
ulcerations left lower leg, toes
on the right foot,
spontaneous
amputation of parts
of the fingers
complete paralysis
(0/5) distal right LL,
paresis fingers
normal ulnar
motor NCV
(60.0 m/s), EMG
neurogenic
no
Family 4 (CMT-869)
Belgium
HSANII
II:1 CG 8 panmodal distal
sensory loss
ulcerations,
hyperkeratosis
hand palms,
nail dystrophy
terminal phalanx
digit II right side
distal > proximal
LL and UL.
Severe dorsiflexor
weakness
in feet, weakness
hipflexors
SNAPs reduced to absent
in sural and median nerve;
reduced CMAP amplitudes
with borderline NCV for
median and fibular nerve,
EMG neurogenic
slow speech
development
with bad
articulation;
IQ of 80 normal
MRI scan
of the brain
Charcot joint deformities in the
terminal phalanges; difficult gait,
pronounced equinus deformities,
wheelchair, small stature
None of the affected individuals had autonomic dysfunction. Abbreviations are as follows: PID, individual identification from pedigree (see Figure 4A); AOO, age of onset;l AE, age at last exam; CG, congenital; UL, upper limbs;
LL, lower limbs; SNAP, sensory nerve action potential; NCV, nerve conduction velocity; EMG, electromyogram; CMAP, compound muscle action potential; IQ, intelligence quotient; MRI, magnetic resonance imaging. Both
Belgian families are of European ancestry; see Rotthier et al.17 for further discussion on family 3 (CMT-155).
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Figure 5. Analysis of Human-Tissue Expression of the KIF1A Messenger Containing Exon 25b
(A) Diagram of KIF1A cDNA from the first coding exon (x2) to the last exon (x47). Exon 25b is in red. The numbered arrows indicate the
primers (listed in Table S1) used for PCR experiments on cDNA samples.
(B) PCR amplifications with cDNAs from different tissues. Top: amplifications of a 281 bp product between exon 24 (primer 1) and exon
25b (primer 2). Bottom: amplifications of a 185 bp product between exon 25b (primer 3) and exon 26_27 (primer 4). Beta-actin was
coamplified as an internal control.
(C) Relative quantification of isoforms of KIF1A lacking exon 25b (ex25_26, primers 5 and 7) and KIF1A containing exon 25b (ex25b,
primers 6 and 7) in adult human brain and DRG tissues by real-time quantitative PCR via the 2-DDCT method. POLR2A was used as an
endogenous reference. The brain KIF1A isoform lacking exon 25b was arbitrarily chosen as the calibrator. The bars show the mean 5
SEM for each target.
(D) Long-range PCR amplifications from brain and DRG cDNAs. Left: amplifications between exon 2 (primer 8) and exon 25b (primer 2).
Right: amplifications between exon 25b (primer 3) and exon 47 (primer 9). Beta-actin was coamplified as internal control.
(E) The linear structure of the KIF1A transcript is shown to contain exon 25bon the basis of the sequencing traces of the long-range PCR
products. This isoform contains all the known exons of KIF1A plus exons 13b and 25b (in red).KIF1A mutations will be needed if researchers are to deter-
mine whether such a genotype-phenotype correlation
exists.
Two recent studies reported potential pathogenic muta-
tions in KIF1A. Hamdan et al. identified a de novo
missense mutation in a patient with nonsyndromic intel-
lectual disability,24 and Erlich et al. found a homozygous
missense change in a single consanguineous family with
Hereditary Spastic Paraparesis.25 Both mutations were
located in the kinesin motor domain of KIF1A. Although
these mutations were reported in single families and hence
should be interpreted with caution, it is noteworthy that
all the HSANII patients carrying mutations in KIF1A
present with variable degrees of muscle weakness and
that one of them has a speech delay.
Although we showed that KIF1A interacts with WNK1/
HSN2 and both proteins colocalize along axons of DRG228 The American Journal of Human Genetics 89, 219–230, August 1sensory neurons, the functional role of this interaction
remains unclear. KIF1A did not appear to be responsible
for the presence of WNK1/HSN2 along axons despite its
well-established role in anterograde transport and thediffer-
ential localization between the WNK1 and WNK1/HSN2
isoforms in DRG sensory neurons. Interestingly though,
WNK1 phosphorylation of synaptotagmin-2, which is
transported with synaptic vesicle precursors by KIF1A,18
reduces its binding to phospholipid vesicles.26 In addition,
the phosphorylation state of kinesinsmodulates both cargo
insertion and removal27 and influences the binding of kine-
sins to microtubules.28 Therefore, it can be hypothesized
that the kinase activity of WNK1/HSN2 regulates the un-
loading of KIF1A cargos at axonal tips of neurons, and
such a hypothesis is consistent with the slightly increased
colocalization of KIF1A and WNK1/HSN2 at the distal
portion of axons (Figure 6C). Of note, the two frameshift2, 2011
Figure 6. Localization of KIF1A and WNK1/HSN2 and Silencing of KIF1A in Adult Mouse DRG Neurons
(A–E) Sequential laser confocal scans to compare the localization of KIF1A andWNK1/HSN2. Neurons were cultured 48 hr prior to their
immunodetection. KIF1A andWNK1/HSN2 colocalize well, as evidenced by the use of anti-KIF1A (A, green), anti-HSN2 (B, red) and anti-
betaIII tubulin (blue).
(C) Merged image of (A) and (B); strong colocalization of green and red is yellow.
(D) Merged image of (C) and the matching betaIII tubulin detection; strong colocalization of red and blue is pink.
(E) Enlargement of the boxed image area in (D).
(F–J) Lentiviral shRNA-mediated knockdown of KIF1A. Twenty-four hours after their plating, primary neurons were infected overnight
with lentiviral particles expressing shRNA (kif46) so that KIF1Awould be silenced. (F) Immunoblot analysis confirmed the knockdown of
KIF1A in neurons infected by lentivirus expressing shRNA against KIF1A (Kif43 and Kif46). Control lysates were prepared from cells
infected with lentiviruses expressing shRNA against GFP, and an actin antibody showed equal loadings. Cells were grown for 4 days after
infection before their immunodetection with anti-KIF1A (G, green), anti-HSN2 (H, red), and anti-betaIII tubulin. (I) Merged image of (G)
and (H). (J) Merged image of (I) and the matching betaIII tubulin detection (blue).mutations identified here are located downstream of the
motor and the Forkhead-associated (FHA) domains of
KIF1A, but both are predicted to affect the C-terminal lipid
binding Pleckstrin homology (PH) domain (Figure 4C),
which is necessary for vesicle transport.29
Although the functional relationship between KIF1A and
WNK1/HSN2andthe roleof theKIF1Aexon-25b-containing
isoform remain to be elucidated, this study identifies muta-
tions of KIF1A as a rare cause of HSANII and provides clues
to the pathogenesis of HSANII and the function of WNK1/
HSN2 in addition to further emphasizing the essential role
of KIF1A in the peripheral nervous system. Finally, for both
WNK1 and KIF1A, the mutations were largely restricted to
alternatively spliced exons, underscoring the importance
of alternative splicing in the peripheral nervous system.Supplemental Data
Supplemental Data include one figure and one table and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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